Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kisspeptin and Beta-Cell Responsivity in Healthy Women
NCT04532801Phase 1Withdrawn
- Start
- Sep 2019
- Primary completion
- Aug 2024
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised trial of kisspeptin 112-121 in type 2 diabetes mellitus (T2DM). Primary endpoint: Beta-cell responsivity index at 6 months. Planned start Sep 2019; status: withdrawn.
02
Drugs
kisspeptin 112-121
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04532801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04532801.